[Management of cutaneo-mucosal herpes in immunocompetent patients (ocular manifestations excluded)].
D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002675:Child, Preschool; D004279:DNA, Viral / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D005602:France; D006558:Herpes Genitalis / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D006560:Herpes Labialis / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D006561:Herpes Simplex / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy / Q000635:transmission; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D006559:Pemphigoid Gestationis / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D012008:Recurrence; D018139:Simplexvirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D013283:Stomatitis, Herpetic / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D013997:Time Factors
D000914:Antibodies, Viral; D000998:Antiviral Agents; D004279:DNA, Viral; D000212:Acyclovir